Our findings will require validation in a larger patient cohort, use of sequentially obtained plasma cells during the course of MGUS to MM progression, as well as improvements in analytical capabilities by analyzing many more cells per patients and the inclusion of unique molecular indexes (UMIs) during the cDNA synthesis to validate whether combination regimens including proteasome inhibitors and mTOR inhibitors could improve MM treat and overcome drug resistance in MM and RRMM. The gene discussed is MTOR; the disease is Miyoshi myopathy.